The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947398/

Peter Radeczky, 1, 2 Zsolt Megyesfalvi, 1, 2, 3 Viktoria Laszlo, 2, 3 Janos Fillinger, 1, 2 Judit Moldvay, 2, 4 Erzsebet Raso, 5 Erzsebet Schlegl, 2 Tamas Barbai, 5 Jozsef Timar, 5, 6 Ferenc Renyi-Vamos, 1, 2 Balazs Dome, 1, 2, 3, * and Balazs Hegedus 7, * KRAS mutation is the most common genetic alteration in lung adenocarcinoma (LADC) in Western countries and is associated with worse outcome in bone-metastatic cases.